- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06178718
A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules
December 20, 2023 updated by: TenNor Therapeutics (Suzhou) Limited
A Phase 1, Single-center, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TNP-2092 Capsules, and the Food Effect on the Pharmacokinetics of TNP-2092 Capsules After Single-dose Oral Administration in Healthy Subjects
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.
Study Overview
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jilin
-
Changchun, Jilin, China
- The First Hospital of Jilin University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Sex: male or female;
- Age: 18-45 years, inclusive;
- BMI: 19.0-26.0 kg/m2, inclusive;
- Female subjects of childbearing potential must agree to practice abstinence or take effective contraceptive measures during the study and at least 70 days (10 weeks) after administration;
- Male subjects must agree to practice abstinence or use condoms as a contraceptive measure during the study and at least 70 days (10 weeks) after administration;
- Subjects whose clinical laboratory test results are within the normal range or whose test results are abnormal, but judged by the investigator to be of no clinical insignificance;
- Those who do not smoke, or have smoked less than 5 cigarettes per day within 3 months before screening; those who do not drink alcohol, or have drunk less than - units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine) within 6 months before screening; those who have not smoked or drunk alcohol within 48 hours before admission to the study site;
- Those who are fully informed of and understand this study, and have signed the Informed Consent Form;
- Those who are willing to follow and able to complete all the study procedures.
Exclusion Criteria:
- Those with symptoms or medical history of cardiovascular, digestive, respiratory, urinary, neurological, blood, immune, endocrine system diseases or tumor, mental illness, or any situation which, in the opinion of the investigator, may threaten the safety of the subjects or affect the correctness of the study results;
- Pregnant or lactating women;
- Those whose blood pressure above 150/90 mmHg or below 85/55 mmHg (supine position);
- Those with regular use of any prescription/over-the-counter drugs, including vitamins, minerals, nutritional supplements or herbs, within 2 weeks before enrollment and during the study;
- Those who are HIV positive, syphilis positive, hepatitis B surface antigen positive, hepatitis C antibody positive, and/or with a positive drug urine test result;
- Those who have a history of alcohol or drug abuse in the past 10 years; Those with an allergic constitution, a history of allergic diseases or a history of drug allergy;
- Those who have had beverages or foods containing methylxanthine (coffee, tea, coke, chocolate and energy drinks), grapefruit (fruit juice) and alcohol within 48 hours (2 days) before the clinical study;
- Those who have taken any drug that changes the activity of liver enzymes within 28 days before taking the investigational product or during the study;
- Those who have donated blood within 3 months before enrollment;
- Those who have participated in any clinical studies within 3 months before enrollment;
- Those who are the staff of the study site directly affiliated to this study or are their immediate family members. Immediate family members are defined as spouses, parents, children or siblings, whether related by blood or legally adopted;
- Those who are employees of TenNor Therapeutics;
- Other circumstances deemed by the investigator to be unsuitable for the subject to participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
The Placebo will be administered once in each group.
|
Experimental: TNP-2092 capsules 100mg
|
The drug will be administered once in each group.
Other Names:
The Placebo will be administered once in each group.
|
Experimental: TNP-2092 capsules 200mg
|
The drug will be administered once in each group.
Other Names:
The Placebo will be administered once in each group.
|
Experimental: TNP-2092 capsules 400mg (Food effect study Group A)
After completed the single ascending dose study, the participant will convert to the food effect study.
The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days.
|
The drug will be administered once in each group.
Other Names:
The Placebo will be administered once in each group.
|
Experimental: TNP-2092 capsules 800mg
|
The drug will be administered once in each group.
Other Names:
The Placebo will be administered once in each group.
|
Experimental: TNP-2092 capsules 1200mg
|
The drug will be administered once in each group.
Other Names:
The Placebo will be administered once in each group.
|
Experimental: Food effect study Group B (TNP-2092 capsules 400 mg)
The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days.
|
The drug will be administered once in each group.
Other Names:
The Placebo will be administered once in each group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Adverse Events (AEs)
Time Frame: Day 1 to Day 4
|
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Preexisting conditions which worsen during a study are also considered as Adverse Events.
|
Day 1 to Day 4
|
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)
Time Frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
|
Plasma concentrations of TNP-2092 were measured by a specific and validated assay.
Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods
|
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
|
Area Under the Plasma Concentration Versus Time Curve from 0 to the Last Measurable Concentration (AUC0-t)
Time Frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
|
Plasma concentrations of TNP-2092 were measured by a specific and validated assay.
Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
|
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
|
Maximum Observed Plasma Concentration (Cmax) of TNP-2092
Time Frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
|
Plasma concentrations of TNP-2092 were measured by a specific and validated assay at specified time points
|
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 6, 2016
Primary Completion (Actual)
July 30, 2016
Study Completion (Actual)
July 30, 2016
Study Registration Dates
First Submitted
December 7, 2023
First Submitted That Met QC Criteria
December 20, 2023
First Posted (Actual)
December 21, 2023
Study Record Updates
Last Update Posted (Actual)
December 21, 2023
Last Update Submitted That Met QC Criteria
December 20, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TNP-2092-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperammonemia
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; Lawson Wilkins Pediatric Endocrine SocietyWithdrawn
-
Elizabeth A RosenfeldNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedHyperinsulinism-Hyperammonemia SyndromeUnited States
-
Liminal BioSciences Ltd.TerminatedHyperammonemiaUnited Kingdom
-
TenNor Therapeutics (Suzhou) LimitedCompleted
-
Institute of Liver and Biliary Sciences, IndiaCompleted
-
University Hospital, GhentRecruitingHyperammonemic EncephalopathyBelgium
-
Children's Mercy Hospital Kansas CityWithdrawnHypoglycemia | Seizures | HyperammonemiaUnited States
-
Mendel TuchmanEunice Kennedy Shriver National Institute of Child Health and Human Development...UnknownInborn Errors of MetabolismUnited States
-
Groupe Hospitalier Pitie-SalpetriereCompletedMetabolic Disease | Adverse Drug Event | Hyperammonemia | Drug ToxicityFrance
-
Recordati Rare DiseasesTarget PharmaSolutions, Inc.RecruitingPropionic Acidemia | Methylmalonic Acidemia | HyperammonemiaUnited States
Clinical Trials on TNP-2092
-
TenNor Therapeutics LimitedCompletedProsthetic Joint InfectionUnited States
-
TenNor Therapeutics LimitedCompleted
-
TenNor Therapeutics Inc.Completed
-
TenNor Therapeutics (Suzhou) LimitedCompleted
-
TenNor Therapeutics LimitedCompletedGram-Positive Bacterial Infections | Skin and Subcutaneous Tissue Bacterial InfectionsUnited States
-
TenNor Therapeutics Inc.CompletedHelicobacter Pylori InfectionChina
-
TenNor Therapeutics Inc.CompletedAcute Bacterial Skin and Skin Structure Infection (ABSSSI) | Prosthetic Joints Infection (PJI)China
-
TenNor Therapeutics (Suzhou) LimitedCompleted
-
TenNor Therapeutics (Suzhou) LimitedCompleted
-
TenNor Therapeutics (Suzhou) LimitedCompleted